FMD and AAA Risk Assessment Using Targeted SNP Panels
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective ways to determine the risk of fibromuscular dysplasia (FMD) and abdominal aortic aneurysm (AAA) in family members of individuals with FMD, particularly in male relatives, and there is a need for methods to assess and manage symptoms and risks associated with these conditions.
Innovation Solution
A biomarker-based approach involving the analysis of specific single nucleotide polymorphisms (SNPs) to calculate risk scores for FMD and AAA, including the use of panels such as rs9349379, rs6580732, and others, to assess the risk and administer prophylactic and symptom management regimes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional vascular disease risk assessment methods are used, then general population screening can be performed, but they fail to accurately determine FMD risk in family members particularly male relatives
Solution Approach 1:
The patent applies local quality by creating gender-specific and family-history-specific risk assessment protocols. Male relatives with FMD-affected relatives receive targeted screening using specific SNP panels and risk calculation methods that differ from female relatives or general population screening, optimizing accuracy for each subgroup
Solution Approach 2:
The patent changes the assessment parameters from traditional vascular risk factors to genetic biomarkers (SNPs). By using polygenic risk scores based on specific genetic variants, the system achieves higher precision in FMD risk prediction while maintaining adaptability across different family member categories
2Measurement precision
If comprehensive genetic biomarker panels are analyzed, then FMD risk prediction accuracy is improved, but testing complexity and cost increase
Solution Approach 1:
The patent segments the genetic biomarker analysis into focused SNP panels tailored to specific risk groups. Rather than analyzing the entire genome, selected SNPs relevant to FMD and AAA risk are tested, reducing complexity while maintaining predictive accuracy for targeted populations
Solution Approach 2:
The patent creates a universal risk assessment framework that uses the same core genetic biomarkers to evaluate multiple conditions (FMD and AAA) across different population groups. This multi-functional approach simplifies the testing system while maintaining comprehensive risk evaluation
3Reliability
If early risk identification in family members is implemented, then preventive treatment can be administered, but screening of all family members increases healthcare resource requirements
Solution Approach 1:
The patent implements preliminary genetic risk assessment to identify high-risk individuals before clinical symptoms develop. By screening family members using targeted biomarker panels, the system enables early intervention in those most likely to benefit, avoiding unnecessary screening of low-risk individuals and optimizing healthcare resource allocation
Data Source
AI summary
Provided herein are systems and methods for determining a subject's risk of fibromuscular dysplasia (FMD) and/or abdominal aortic aneurysm (AAA), and methods of treatment and symptom management based thereon.